<DOC>
	<DOCNO>NCT02261779</DOCNO>
	<brief_summary>Longterm disease-free survival ( DFS ) old patient acute myeloid leukemia ( AML ) remain poor . The vast majority AML patient relapse within two year start therapy1,2 . In Acute Promyelocytic Leukemia ( APL , AML M3 ) , all-trans-retinoic-acid ( ATRA ; Tretinoin ) induce differentiation subsequently clinical remission . So far effective differentiation therapy exist AML subtypes . Recent preclinical data suggest combinatorial use ATRA tranylcypromine ( TCP ) , irreversible Monoamine-Oxidase ( MAO ) Lysin-specific demethylase ( LSD ) inhibitor also inhibit LSD1 ( histone H3 Lysine 4 demethylase ) , induce leukemia cell differentiation leukemic stem cell exhaustion vitro vivo non-APL AML subtypes . In Phase I/II study investigator explore feasibility , safety , well efficacy Tretinoin/TCP treatment patient relapse refractory AML patient AML eligible intensive treatment . Patients treat daily increase dos TCP ( initially 10 mg/day , +10 mg day 80mg/d ) . After 7 day , ATRA add fix dose ( 45 mg/sqm/day ) . Overall , 16 evaluable patient go treat . The primary endpoint fraction patient achieve CR , CRp ( complete response incomplete recovery platelet ) , CRi ( complete response incomplete recovery granulocyte ) PR . Secondary endpoint tolerability , safety well progression-free survival overall survival . Serum level TCP regularly analyze . Pharmacodynamic analyse perform analysis inhibition LSD1 TCP . Further analyse address change Histone H3 lysine 4 tri demethylase ( H3K4me3 ) level AML blast differentiation status AML blast . Taken together , Phase I/II study analyze feasibility , pharmacodynamics effectivity ATRA TCP differentiation therapy AML .</brief_summary>
	<brief_title>Phase I/II Trial ATRA TCP Patients With Relapsed Refractory AML Intensive Treatment Possible</brief_title>
	<detailed_description />
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Tranylcypromine</mesh_term>
	<criteria>1 . Subjects must provide write informed consent prior performance studyspecific procedures assessment routinely perform diagnosis monitoring AML , subject must willing comply treatment follow assessment procedures 2 . Histologically cytologically confirm diagnosis AML relapse refractory least one induction regimen , patient AML initial diagnosis eligible allogeneic transplant intensive induction chemotherapy ( investigator´s choice ; example reduce general state ) , except AML M3 ( acute promyelocytic leukemia ) . 3 . Age &gt; 18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤3 ( see Appendix , 3.2 ) 5 . Measurable disease burden ( blast bonemarrow ( BM ) and/or peripheral blood ( PB ) , extramedullary blast [ chloroma ] ) 6 . Able swallow retain oral medication 7 . A life expectancy least 4 week 8 . Adequate contraception method 9 . Adequate organ function 1 . Patients 20.000/µl leukocyte peripheral blood control Hydroxyurea . 2 . Patients valid option intensive chemotherapy and/ stem cell transplantation . ( Patients allogeneic stem cell transplant must immunosuppressive agent least 2 week prior study entry Graft versus host disease must resolve Grade &lt; = 2 ) 3 . Patients less 30 % blast bone marrow time diagnosis . They receive Azacytidine monotherapy . 4 . History cancer accord Investigator might confound assessment endpoint study 5 . Uncontrolled peptic ulcer disease clinically significant gastrointestinal abnormality interfere oral dose unstable serious concurrent condition ( e.g. , active uncontrolled infection ) 6 . Poorly control hypertension ( define systolic blood pressure ( SBP ) ≥170 mmHg ) . Note : Initiation adjustment antihypertensive medication permit prior study entry . BP must reassess two occasion separate minimum 1 hour ; occasion , mean ( 3 reading ) SBP/ DBP ( diastolic blood pressure ) value BP assessment must &lt; 140/90 mmHg order subject eligible study . 7 . Prolongation correct QT interval ( QTc ) &gt; 480 m 8 . History one follow cardiovascular condition within past 6 month : cardiac angioplasty stenting , myocardial infarction ( MI ) , unstable angina , symptomatic peripheral vascular disease , class 3 4 congestive heart failure , define New York Heart Association ( NYHA ) 9 . Left ventricular ejection fraction ( LVEF ) least 40 % multiple gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) 10 . History cerebrovascular infarction bleeding , pulmonary embolism ( PE ) , untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anti coagulant agent least 6 week eligible 11 . Evidence serious active bleeding bleed diathesis ( except bleed petechia due AML relate thrombocytopenia treat use platelet transfusion ) . Also , patient know endobronchial lesion and/ lesion infiltrate major pulmonary vessel exclude study due excess risk bleeding . 12 . Prior major surgery trauma within 28 day prior first dose study drug 13 . Treatment investigational agent within 21 day 5 halflife , whichever long prior first dose study drug . 14 . Concurrent cytoreductive chemotherapy except hydroxyurea . 15 . Known immediate delay hypersensitivity reaction idiosyncrasy Tretinoin , Retinoids , soya , peanut Tranylcypromine . 16 . Patients psychological , familial , sociological , geographical condition permit compliance protocol 17 . Patients know epilepsy patient know psychiatric affection ( bipolar disorder , schizophrenia , suicidal patient ) 18 . Pregnant lactate actively breastfeed patient 19 . Patients indignant comply nutritional condition ( see Protocol ) 20 . Poorly adjust diabetes mellitus 21 . Patients hereditary GalactoseIntolerance , LactaseIntolerance GlucoseGalactoseMalabsorption 22 . Known drug alcohol abuse 23 . Phaeochromocytoma carcinoid tumor 24 . Known cerebral vascular disease malformation vessel ( e.g . aneurysma ) 25 . Diabetes insipidus 26 . Patients take follow prohibit medication due interaction ) tretinoin b ) TCP .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>